Special 12/2012

  • BIO-Regions in the European Union

    In an era of tight purse-strings when it comes to collecting capital for long-term projects like drug development, the concentration of know-how in a biotech cluster, incubator or meta-cluster offers bio­tech companies many advantages. Access to a common infrastructure and networks, better visibility for potential corporate and VC investors, and improved access to public funding are only a few of them. Well­­-established biotech hubs also exert an irresistible appeal to national and EU policymakers. They of course are seeking to create high-paying jobs, attract new companies as well as investors and stimulate the socioeconomic growth of entire regions (see p. 38). In this special, EuroBio­techNews presents some of the strategies that European bio-incubators are implementing in their quests to become the next major global hub.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/12.html

Kurszettel

Alle Kurse

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014